Seattle Genetics reported $568.85M in Current Liabilities for its fourth fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Liabilities Change
Agios Pharmaceuticals AGIO:US $ 59.83M 1.93M
Bayer BAYN:GR € 29403M 676M
Celldex Therapeutics CLDX:US $ 14.56M 1.97M
Daiichi Sankyo 4568:JP Y 355195M 19149M
Eisai 4523:JP Y 304993M 24164M
Genmab GEN:DC DK 1339M 229M
Immunogen IMGN:US $ 84.12M 16.83M
Mirati Therapeutics MRTX:US $ 123.57M 20.09M
Nektar Therapeutics NKTR:US $ 85.2M 54.77M
Novartis NOVN:VX SF 30208M 328M
Spectrum Pharmaceuticals SPPI:US $ 39.21M 14.02M
Teva Pharmaceutical TEVA:IT 11.03B 798M
Xencor XNCR:US $ 60.94M 9.8M